Research on Safety and Efficacy of Adjunctive Intra-arterial adenosine following Successful Endovascular Thrombectomy in Patients with Large Vessel Occlusion Acute Ischemic Stroke

Start Date11 Nov 2024

Sponsor / Collaborator-

NCT06717685 / RecruitingPhase 3IIT

Comparison of Verapamil With Adenosine After Vagal Maneuvers in Patients Presenting With Paroxysmal Supraventricular Tachycardia (pSVT), in a Tertiary Care Hospital of Lahore, Pakistan

Supraventricular tachycardia (SVT) is a term widely used to describe tachycardial dysrhythmias, paroxysmal SVT (PSVT) is a narrow term including only AV nodal re-entrant tachycardia (AVNRT) and atrioventricular re-entrant tachycardia (AVRT), both of which can cause discomfort and, in some cases, life-threatening symptoms.
Usually Carotid sinus massage is done to lower the pulse rate and after the standard time specific verapamil dose is administered. In this study after carotid sinus massage Conventional Valsalva or modified Valsalva maneuver will be randomly applied. In case, the normal sinus rhythm (NSR) is not achieved then verapamil of or adenosine dose will be administered to the patients after after taking the consent.

Start Date28 Oct 2024

Sponsor / Collaborator

Rashid Latif Medical College

[+1]

NCT06578234 / RecruitingPhase 4

Hyperemic mYocardial Perfusion by adEnosine at diffeRent Doses

Adenosine is a commonly used pharmaceutical stressor at cardiac magnetic resonance examinations to assess suspected chronic coronary syndrome (CCS). However, several studies have reported that the current use of adenosine does not induce adequate hyperemic response in a substantial number of patients, leading to false diagnostics. The aim of this trial is to investigate the hyperemic effect of the standard dose of adenosine (140 microgram/kg/min) to the high dose of adenosine (210 microgram/kg/min) to improve the diagnostic methods using adenosine as a stressor and ultimately improve treatment decisions and patient prognosis in CCS.

Start Date23 Oct 2024

Sponsor / Collaborator

Region Skåne Holding AB

100 Clinical Results associated with Adenosine

100 Translational Medicine associated with Adenosine

100 Patents (Medical) associated with Adenosine

12,275

Literatures (Medical) associated with Adenosine

01 Jan 2025·AMERICAN JOURNAL OF CARDIOLOGY

Evaluation of Intravenous Versus Intracoronary Adenosine in Coronary Reactivity Testing

Article

Author: Kumar, Y. Darren ; Al-Azizi, Karim ; Widmer, R Jay ; Potluri, Srini ; Exaire, Jose Emilio ; Widmer, R. Jay ; Mixon, Timothy A ; Kumar, Y Darren ; Dalal, Fazal ; Escobedo, Yissela ; Mixon, Timothy A.

Coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) obtained through coronary bolus thermodilution are used to assess and treat patients with angina and no obstructive coronary artery disease. Previous studies demonstrate comparable results assessing epicardial ischemia by fractional flow reserve using intravenous (IV) or intracoronary (IC) adenosine. It is unknown if there is a similarity between IC and IV hyperemia with adenosine when performing coronary reactivity testing (CRT). We reviewed CRT data and baseline demographics in a cohort of patients who underwent CRT for ischemia and no obstructive coronary artery disease. We evaluated CFR and IMR in patients whereby maximal hyperemia was obtained by both IC and IV means using linear regression, one-way analysis of variance, Wilcoxon, and Bland-Altman analysis. We assessed 62 patients with a median age of 60.5 years (50 to 67), and 72% were females. The average CFR with IC adenosine was 3.12 (2.31 to 4.06) and 2.71 (2.0 to 3.88) with IV adenosine, with an R² value of 0.50 (p <0.0001). The average IMR with IC adenosine was 28.23 (16.24 to 50.72) and 22.27 (14.79 to 37.0) with IV adenosine, with an R² value of 0.33 (p <0.0001). Average intra-method variability between IC and IV adenosine was nonsignificant (p = 0.31 for CFR and p = 0.55 for IMR). Bland-Altman analysis showed reasonable agreement between IV and IC adenosine for CFR and IMR with slightly higher values using IC adenosine. Therefore, in CRT with bolus thermodilution, CFR and IMR values obtained with IC adenosine correlate well with those obtained with IV adenosine. This presents a potential alternative to IV adenosine for bolus thermodilution CRT.

01 Jan 2025·NEUROPHARMACOLOGY

Adenosine regulates depressive behavior in mice with chronic social defeat stress through gut microbiota

Article

Author: Li, Qu-Peng ; Hao, Jing-Ru ; You, Yue ; Zhang, Hao ; Liu, Le ; Wang, Wei ; Tong, Kun ; Sun, Nan ; Chen, Yuan-Hao ; Gao, Can ; Huang, Yao

Major depressive disorder (MDD) is recognized as the most prevalent affective disorder worldwide. Metagenomic studies increasingly support a critical role for dysbiosis of gut microbiota in the development of depression. Previous studies have demonstrated that adenosine alleviates gut dysbiosis, suggesting that elevating adenosine levels could be a novel intervention for MDD; however, the mechanisms underlying this effect remain unclear. This study utilized 16S rRNA gene sequencing, fecal microbiota transplantation (FMT) and ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) to test the hypothesis that increased adenosine alleviates depressive behaviors in male mice subjected to chronic social defeat stress (CSDS) through alterations to gut microbiota. The data showed that depression-susceptible (SUS) mice exhibited gut dysbiosis, and FMT from SUS mice increased depression-like behaviors in healthy recipients. In SUS mice, adenosine supplementation ameliorated both depression-like behaviors and abnormalities in gut microbiota, and co-administration of probiotics and adenosine not only mitigated depression-like behaviors but also enhanced gut barrier integrity. By including 83 depressed adolescents and 67 healthy controls, this study found that the level of short-chain fatty acids (SCFAs) in the depression group was reduced, this finding parallels reductions seen in SUS mice and in recipient mice after FMT from SUS donors. Conversely, supplementation with either adenosine or probiotics led increased SCFAs concentrations in the serum of SUS mice. These findings suggest that adenosine may alleviate depression-like behaviors in CSDS mice by modulating the gut microbiota. This effect is likely associated with increased serum SCFAs, metabolites produced by the gut microbiota, following adenosine supplementation. This article is part of the Special Issue on "Personality Disorders".

09 Dec 2024·Journal of biomolecular structure & dynamics

Integrating network pharmacology with molecular docking for elucidation of molecular biological mechanisms of Jiedu Qingjin formula for non-small cell lung cancer

Article

Author: Dan, Wenchao ; Zhang, Xiaoxiao ; Han, Yingying ; Wang, Xinmiao ; Song, Xiaotong ; Li, Jie ; Wu, Jingyuan ; Xu, Bowen ; Qin, Xiaoyan

Traditional Chinese medicine is an important part of complementary alternative medicine. Jiedu Qingjin formula (JDQJF) is an effective national invention patent for the treatment of non-small cell lung cancer (NSCLC). We investigated the molecular biological mechanisms based on network pharmacology, molecular docking, and molecular dynamics simulations. Compounds of JDQJF were screened through the TCMSP, ETCM, and literature. Targets were searched by DrugBank and predicted by SwissTargetPrediction. GEO database was applied for screening differentially expressed genes between cancerous tissues and healthy tissues of NSCLC. Subsequently, the protein-protein interaction between JDQJF and NSCLC were obtained by Cytoscape. Visual analyses were carried out to extract candidate genes, then subjected to Metascape for enrichment analyses. Finally, molecular docking was performed by AutoDock, and the best complexes were subjected to molecular dynamics simulation and binding energy calculations by MMPBSA. A total of 273 compounds, 390 targets, 3146 GO terms, and 174 KEGG pathways were obtained. Five potential compounds (quercetin, adenosine, apigenin, heptadecanoic acid, and luteolin) were notably modulated by key targets AKT1, MAPK3, and RAF1. Enrichment results included cell cycle process, growth transduction factor, immune response-activating transduction, and involved PI3K/AKT, MAPK, NF-κB and VEGF pathway. RAF1-quercetin showed the highest binding affinity (-9.1 kcal/mol), revealed stable interactions during the simulation, and the highest estimated relative binding energy of the RAF1-Heptadecanoic was -184.277 kcal/mol. This study suggested that EMT-related, inflammation-related, immune-related, and angiogenesis-related pathways may be associated with JDQJF, and involved in the advancement of NSCLC, which points out the research direction for subsequent utility mechanism validation.Communicated by Ramaswamy H. Sarma.

News (Medical) associated with Adenosine

27 Aug 2024

·www.globenewswire.com

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update

Exploration and evaluation of strategic alternatives continueWESTPORT, Conn., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal quarter ended June 30, 2024. “We continue to explore strategic alternatives. These may include finding a partner for one or more of our assets, a sale of our company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions,” said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage. “We are encouraged by the two advanced patients that continue on PORT-6 beyond 6 months who we continue to follow, and we plan to replace one patient in the ADPORT-601 trial who withdrew prior to dose limiting toxicity assessment for an unrelated adverse event. We also continue our collaborations with numerous experts to further understand the biology and utility of our product candidates,” continued Dr. Walters. Financial Results for the Quarter Ended June 30, 2024 The Company incurred a net loss of approximately $1.7 million during the three months ended June 30, 2024 (the “Fiscal 2025 Quarter”), compared to a net loss of approximately $4.2 million during the three months ended June 30, 2023 (the “Fiscal 2024 Quarter”), representing a $2.5 million decrease in net loss. Operating expenses, including research and development (“R&D”) costs and general and administrative (“G&A”) expenses, were $2.8 million in the Fiscal 2025 Quarter, down from $5.0 million in the Fiscal 2024 Quarter, a decrease of $2.2 million, as detailed below. R&D costs decreased by approximately $2.3 million, or 64%, from $3.6 million in the Fiscal 2024 Quarter, to $1.3 million in the Fiscal 2025 Quarter. This reduction was primarily due to the winding down of clinical trial costs (principally CRO-related), which decreased by $0.3 million, from $1.0 million in the Fiscal 2024 Quarter to $0.7 million in the Fiscal 2025 Quarter, as the Company paused enrollment in its sponsored clinical trials in the third and fourth quarters of the fiscal year ended March 31, 2024. Manufacturing-related costs decreased by $0.7 million, from $0.8 million in the Fiscal 2024 Quarter to $0.1 million in the Fiscal 2025 Quarter. These decreases reflect reduced clinical activity and manufacturing costs following the Company’s decision to discontinue the iNKT program and pause further patient accrual in the adenosine program. Additionally, R&D non-cash share-based compensation expense decreased from $0.4 million in the Fiscal 2024 Quarter to nil in the Fiscal 2025 Quarter. Payroll-related expenses also decreased by $0.2 million, from $0.5 million in the Fiscal 2024 Quarter to $0.3 million in the Fiscal 2025 Quarter, due to the resignation of two employees in January 2024. Further, in the Fiscal 2024 Quarter, the Company incurred a $0.5 million milestone payment for dosing its first adenosine patients. Consulting fees decreased by $0.1 million, from $0.2 million in the Fiscal 2024 Quarter to $0.1 million in the Fiscal 2025 Quarter, reflecting the decline in consulting-related activity. Lastly, there was a $0.1 million decrease in fees paid related to the transition of the iNKT study before its discontinuation. G&A expenses increased by $0.1 million, or 7%, from $1.4 million in the Fiscal 2024 Quarter to $1.5 million in the Fiscal 2025 Quarter. Professional fees increased by $0.1 million, from $0.5 million in the Fiscal 2024 Quarter to $0.6 million in the Fiscal 2025 Quarter, primarily due to legal fees associated with regulatory filings, corporate matters, and related audit fees. Payroll-related expenses increased by $0.4 million from $0.2 million in the Fiscal 2024 Quarter to $0.6 million in the Fiscal 2025 Quarter due to the amounts associated with retention agreements executed with an employee and a consultant. Additionally, G&A non-cash share-based compensation expense decreased by $0.2 million due to the continued vesting of stock options with higher fair values, partially offset by recording all Fiscal 2025 Quarter share-based compensation expense as G&A expenses as the result of the discontinuation of the iNKT study and the pause of further patient accrual in the adenosine program. Directors’ fees also decreased by $0.1 million in the Fiscal 2025 Quarter, as all directors, except for two who resigned in April 2024, waived their fees. The primary reasons for the quarter-over-quarter differences in the Company’s pre-tax items of income and expense were the $1.1 million non-cash gain from the change in the fair value of certain warrants accounted for as liabilities, issued in connection with an equity offering in October 2023, in the Fiscal 2025 Quarter, and the non-cash loss from the increase in the fair value of the deferred purchase price payable to the former Tarus shareholders and the deferred obligation for the iOx milestone, totaling $1.1 million, in the Fiscal 2024 Quarter. As of June 30, 2024, the Company had cash and cash equivalents of approximately $3.3 million and total current liabilities of approximately $3.0 million. About Portage Biotech Inc. Portage is a clinical-stage immuno-oncology company with a portfolio of multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. The Company has made the decision to discontinue its sponsored trial for its the invariant natural killer T-cell (iNKT) program and pause further patient accrual to its sponsored adenosine trial program (ADPORT-601 trial) for its potentially best-in-class adenosine antagonists PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor). The Company is exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a company wind down, further financing efforts or other strategic actions. For more information, please visit www.portagebiotech.com, follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc. Forward-Looking Statements All statements in this news release, other than statements of historical facts, including without limitation, statements regarding about the Company’s information that are forward-looking in nature and, business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words "believe," "expects," "anticipates," "intends," "estimates," “will,” “may,” “plan,” “potential,” “continue,” or similar expressions or variations on such expressions are forward-looking statements. For example, statements regarding the Company's plans to continue exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings (both in and out of court), a company wind down, further financing efforts, or other strategic actions, the Company’s expectation to replace one patient in the ADPORT-601 trial, and the Company’s plans to continue its collaborations with numerous experts to further understand the biology and utility of its product candidates are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but are not limited to: the Company's plans and ability to develop and commercialize product candidates and the timing of these development programs; the Company's clinical development of its product candidates, including the results of current and future clinical trials; the benefits and risks of the Company's product candidates as compared to others; the Company's maintenance and establishment of intellectual property rights in its product candidates; the Company's ability to obtain financing in the future to cover its operational costs and progress its plans for clinical development, its estimates regarding its capital requirements, and its ability to continue as a going concern; the Company’s estimates of future revenues and profitability; the Company's estimates of the size of the potential markets for its product candidates; its selection and licensing of product candidates; and other factors set forth in “Item 3 - Key Information-Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2024. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law. FOR MORE INFORMATION, PLEASE CONTACT:Investor Relations:ir@portagebiotech.com Media Relations:media@portagebiotech.com ---tables to follow--- PORTAGE BIOTECH INC.Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss)(U.S. Dollars in thousands, except per share amounts)(Unaudited) Three Months Ended June 30, 2024 2023 Expenses Research and development $1,305 $3,627 General and administrative expenses 1,534 1,370 Loss from operations (2,839) (4,997)Change in fair value of warrant liability 1,142 – Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone – (1,111)Share of loss in associate accounted for using equity method – (50)Foreign exchange transaction (loss) gain (2) 18 Depreciation expense (8) (11)Interest income, net 45 80 Loss before provision for income taxes (1,662) (6,071)Income tax (expense) benefit (2) 145 Net loss (1,664) (5,926)Other comprehensive income (loss) Net unrealized gain on investments – 1,769 Total comprehensive loss for period $(1,664) $(4,157) Net loss attributable to: Owners of the Company $(1,656) $(5,919)Non-controlling interest (8) (7)Net loss $(1,664) $(5,926) Comprehensive loss attributable to: Owners of the Company $(1,656) $(4,150)Non-controlling interest (8) (7)Total comprehensive loss for period $(1,664) $(4,157) Loss per share Basic and diluted $(1.58) $(6.69) Weighted average shares outstanding Basic and diluted 1,049 885 PORTAGE BIOTECH INC.Condensed Consolidated Interim Statements of Financial Position(U.S. Dollars in thousands)(Unaudited) June 30,2024 March 31,2024 (Audited) Assets Current assets Cash and cash equivalents $3,334 $5,028 Prepaid expenses and other receivables 1,862 2,667 Total current assets 5,196 7,695 Non-current assets Right to use asset 27 35 Other assets, including equipment, net 14 49 Total non-current assets 41 84 Total assets $5,237 $7,779 Liabilities and Equity Current liabilities Accounts payable and accrued liabilities $2,965 $2,836 Lease liability - current, including interest 37 40 Other current liabilities 3 3 Total current liabilities 3,005 2,879 Non-current liabilities Lease liability - non-current – 7 Warrant liability 422 1,564 Total non-current liabilities 422 1,571 Total liabilities 3,427 4,450 Shareholders’ Equity Capital stock 219,500 219,499 Stock option reserve 23,985 23,841 Accumulated deficit (240,974) (239,318)Total equity attributable to owners of the Company 2,511 4,022 Non-controlling interest (701) (693)Total equity 1,810 3,329 Total liabilities and equity $5,237 $7,779 Commitments and Contingent Liabilities

Financial StatementClinical StudyImmunotherapy

16 May 2024

·www.sciencedaily.com

Bioengineered enzyme creates natural vanillin from plants in one step

Vanilla, the most widely used flavoring compound in confectionaries and cosmetics, gets its sweet flavor and aroma from the chemical compound -- 'vanillin'. However, the large-scale production of natural vanillin is impeded by the lack of microbial processes and enzymes which can commercially generate vanillin. Now, researchers have genetically engineered a novel enzyme which can convert ferulic acid from plant waste into vanillin in a one-step sustainable process. Vanilla extract is one of the most widely used flavoring compounds in food products and cosmetics. The pleasant and sweet smell of this classic flavor is imparted by the chemical compound 'vanillin' found in the seed pods of vanilla plants belonging to the orchid family. In plants, vanillin is synthesized by the conversion of ferulic acid by the enzyme -- VpVAN. However, laboratory biosynthesis of vanillin from plant-derived VpVAN yields only very small quantities of vanillin, and is, therefore, commercially impractical. Further, although chemically derived vanilla essences are available cheaply, they do not match the flavor of natural vanilla extract, and the demand for the latter continues to remain high. Additionally, climatic restrictions for the cultivation of vanilla plants, and the relatively small yield obtained per plant, have led to a dwindling supply and a surge in the price of natural vanilla extract. Addressing these challenges, Professor Toshiki Furuya from the Department of Applied Biological Science, Faculty of Science and Technology, Tokyo University of Science, and his graduate students Shizuka Fujimaki and Satsuki Sakamoto, successfully developed an enzyme that generates vanillin from plant-derived ferulic acid. "Ferulic acid, the raw material, is a compound that can be obtained in abundance from agricultural waste such as rice bran and wheat bran. Vanillin is generated simply by mixing ferulic acid with the developed enzyme at room temperature. So, the established technology can provide a simple and environmentally friendly method for producing flavor compounds," explains Prof. Furuya. Their study was published on May 10, 2024 in Applied and Environmental Microbiology. The researchers used genetic engineering approaches to modify the molecular structure of an enzyme -- 'Ado.' Ado is originally an oxidase enzyme that adds an oxygen atom to the substrate -- isoeugenol. In its native state, it does not have the ability to convert ferulic acid into vanillin. Using structural modeling analysis, the researchers were able to predict amino acid changes in Ado which would enable its interaction with ferulic acid. On these lines, they conducted a series of experiments by replacing phenylalanine and valine amino acid residues at specific positions in the structure of Ado, with various other amino acids. They went on to examine the ferulic acid conversion ability of the various engineered mutant proteins. Following several trials and errors, they found that a mutant protein in which only three specific phenylalanine and valine residues were replaced with tyrosine and arginine, stably reacted with ferulic acid and exhibited high conversion activity. Notably, the engineered enzyme did not require any cofactors for conversion, unlike other oxidases, and produced vanillin on a gram scale per liter of reaction solution, with a higher catalytic efficiency and affinity than that of the wild-type enzyme. The reaction only required mixing of the enzyme, ferulic acid, and air (molecular oxygen), at room temperature, making it a simple, sustainable, and economically scalable process. Furthermore, the molecularly evolved enzyme also exhibited conversion activity towards p-coumaric acid and sinapic acid, which are compounds obtained from the degradation of lignin -- a common agricultural waste product. So far, no microbial or plant-derived enzymes have exhibited the ability to convert ferulic acid to vanillin at an industrial scale. Therefore, the enzyme developed in the current study shows considerable potential for enabling the commercial and economically viable production of natural vanillin. Explaining the long-term implications of their research, Prof. Furuya states, "Harnessing the potential of microorganisms and enzymes to derive valuable compounds under mild conditions from renewable plant-based resources, offers a sustainable approach to minimizing environmental footprint. Presently, in collaboration with a company, our research endeavors focus on achieving the real-world implementation of vanillin production through the utilization of the newly developed enzyme."

02 May 2023

·www.fiercebiotech.com

Incyte whittles down pipeline, scrapping 6 R&D programs

Incyte's pipeline cuts will allow the pharma to funnel resources to “programs that can have a high impact for patients and for Incyte," according to CEO Hervé Hoppenot. Incyte is whittling down its R&D pipeline, scrapping six discovery programs—one in a rare form of anemia and five in various cancers—to focus on eight remaining programs. The Jakafi maker’s remaining R&D programs “have high potential,” Incyte CEO Hervé Hoppenot said in a May 2 release. The pipeline trim will allow the pharma to funnel its resources to “programs that can have a high impact for patients and for Incyte." The company has ended phase 3 work on a small molecule PI3K inhibitor—known as parsaclisib—in warm autoimmune hemolytic anemia, citing the “challenging regulatory landscape associated with the PI3K class.” While several PI3K inhibitors have managed to snag FDA approval, the drug class has been frequently tied to serious or even fatal side effects. Last year, the FDA lost confidence in the safety profile of PI3K inhibitors for blood cancers after data from six randomized clinical trials indicated that four marketed PI3K inhibitors may shorten blood cancer patients’ life expectancy because of their toxicity. Since then, the agency said it would put the meds under a more stringent regulatory scope. Incyte’s parsaclisib had also been assessed in a phase 3 trial as a combo treatment alongside the pharma’s approved JAK inhibitor Jakafi for certain cancers. However, the pharma’s first effort at building a better Jakafi regimen ended in failure after an independent data monitoring committee found it was on course to miss the primary endpoint of reducing spleen volume in patients with bone marrow cancer myelofibrosis, and the study was discontinued. Incyte has also ended development of its adenosine program, which includes four separate assets. First on the list is INCB106385, which was being assessed in two separate phase 1 trials among patients with advanced solid tumors. One of those trials also evaluated INCA00186, which is being discontinued, alongside anti-GITR antibody INCAGN1876 in various cancers and INCB81776 in advanced malignancies. All the adenosine programs were discontinued based on early efficacy data, according to Incyte’s release. While Incyte continues to expand the reach of pemazyre—the first FDA-approved drug designed to specifically treat bile duct cancer—in non-U.S. countries, the pharma has ended a phase 2 clinical trial dubbed FIGHT-210 that was testing out the drug in non-small cell lung cancer. So what remains? One of the eight programs the company is zooming in on is INCB123667, a CDK2 inhibitor being studied in a phase 1 trial for patients with advanced malignancies. Another of the surviving programs is INCA33890, a bispecific antibody that has shown anti-tumor effects in preclinical studies. Alongside other discovery programs, Incyte continues to work to expand labels for its approved drugs. Despite the R&D overhaul, the drug developer still seems to be investing in new science for its pipeline. Last month, Incyte paid out $7 million cash to use Biotheryx’s platform to identify and initially develop molecular glue degraders for “multiple historically undruggable oncology targets.” The deal gives Biotheryx the chance to make another $6 million in R&D funding and up to $347 million in milestone payments.

Phase 1Phase 2Drug ApprovalPhase 3Clinical Trial Termination

100 Deals associated with Adenosine

External Link

KEGG	Wiki	ATC	Drug Bank
D00045	Adenosine	C01EB10	DB00640

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	JP	Daiichi Sankyo Co., Ltd.	11 Apr 2005
Tachycardia	CN	Sanofi Winthrop	19 Feb 2000
Tachycardia, Supraventricular	US	Astellas Pharma US, Inc.	30 Oct 1989

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Artery Disease	Phase 1	US	Astellas Pharma US, Inc.	01 Jul 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2024	Not Applicable	Myocardial Bridging	-	Adenosine infusion	ygnofiquby(emdhwfeefg) = plqwhujnff sgmfarijlo (puweideahc, 12) View more	-	31 Aug 2024
				Dobutamine infusion	ygnofiquby(emdhwfeefg) = scupvouonf sgmfarijlo (puweideahc, 13) View more
NCT04392362 (AHAvsSIM, CTgov)	Phase 3	Tachycardia, Supraventricular	30	Adenosine (Intervention Group)	xyjkzgfkap(zanesjabcz) = slvidswmmh uapsvftdso (yrhiosmtaq, tyiylmgbhf - hmdvvdqafd) View more	-	25 Jun 2021
				Adenosine (Control Group)	xyjkzgfkap(zanesjabcz) = miumegkbxs uapsvftdso (yrhiosmtaq, npazouhlet - lwhffohzbx) View more
AAI2021	Not Applicable	-	-	Adenosine Deaminase 1 (ADA-1) (SARS-CoV-2 spike plasmid alone)	ylkteftysg(achbliyogs) = increased odwajzoiao (osuuyhdpql ) View more	-	01 May 2021
				Adenosine Deaminase 1 (ADA-1) (SARS-CoV-2 spike plasmid + ADA plasmid)
ESC2020	Not Applicable	Pulmonary Disease, Chronic Obstructive \| Asthma	780	Regadenoson	oyklxwazro(ntsvtmtzta) = 73% oqtlgpsbyw (qrpznhwnkv ) View more	-	28 Aug 2020
Extreme trial (ESC2019)	Not Applicable	ST Elevation Myocardial Infarction	61	adenosine	qatylodmmb(eyrhrkkbps) = hpxmwxpkxn hlfrcccphx (jtzsleeodh ) View more	-	06 Dec 2019
				adenosine	qatylodmmb(eyrhrkkbps) = gtskwqorgo hlfrcccphx (jtzsleeodh ) View more
ACR2019	Not Applicable	Polymyalgia Rheumatica IL-6 \| adenosine \| equilibrative nucleoside transporter 1 (ENT1)	-	Adenosine (Old Tenocytes)	fchzbedeiw(xwauzbqoeh) = pwurfvrddd leepjtrkur (smidmderti, 194.3)	-	12 Nov 2019
				Adenosine (Young Tenocytes)	fchzbedeiw(xwauzbqoeh) = zavisyqmwz leepjtrkur (smidmderti )
ESC2018	Not Applicable	Atrial Fibrillation First line	151	adenosine	fuyzrdxmrh(ahsboutbdc) = tzlozhjlxt jloartjeok (leoexptbjn )	-	27 Aug 2018
ESC2018	Not Applicable	Atrial Fibrillation adenosine plasma level	-	Adenosine	bgjaaohscb(fhlnkayhmt) = nmyheuhlur abvlnuhwkv (aefnkkixfj ) View more	-	26 Aug 2018
				Adenosine	bgjaaohscb(fhlnkayhmt) = wsthtwvtqx abvlnuhwkv (aefnkkixfj ) View more
NCT03032965 (CTgov)	Phase 2	Atrial Fibrillation	131	Adenosine+Isoproterenol (Adenosine and Isoproterenol)	rwnuqnvljz(jsjyqowobl) = oabgoipctw kdchakcmwx (noumhkjzbh, zwgsogduue - rrsqovmvaq) View more	-	13 Dec 2017
				Isoproterenol (Isoproterenol)	rwnuqnvljz(jsjyqowobl) = mdljhgehxm kdchakcmwx (noumhkjzbh, yzzwkrbebp - libmmnhaue) View more
NCT03231371 (CFR-OHT, CTgov)	Phase 3	Coronary Artery Disease	22	Adenosine	npihctrodx(vgsjarhdlc) = ubxadzbywr yigawaxscz (dtsgaojuov, koqyotddkf - mlomnhxmlb) View more	-	26 Sep 2017

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis